Latest Cost Reduction News

Ryman Healthcare has reported its first positive free cash flow in over a decade, driven by cost reductions and stronger sales momentum, while upgrading its sales guidance for FY26.

PPK Group reports record revenue at Craig International Ballistics and advances lithium sulfur battery technology, while preparing for a CEO transition and focusing on sovereign manufacturing.

First Graphene has locked in a 12-month exclusive global license to develop and sell graphene-enhanced carbon paste, a breakthrough material already boosting solar cell efficiency and cutting costs.

Pacific Edge reports a $19.1 million net loss for the first half of FY26 amid Medicare coverage loss but positions itself for a Medicare-led recovery with strong clinical evidence and a key advisory committee meeting set for February 2026.

Metro Performance Glass Limited has returned to profitability in the first half of 2025, posting a NZD 4.5 million profit before tax and significantly reducing its debt through a NZD 23.9 million equity raise.

Metroglass has reported a 5% revenue decline in its half-year results but achieved a significant reduction in net debt and improved profitability, signaling progress in its turnaround strategy amid challenging market conditions.

Metro Performance Glass reported a surprising 157% jump in net profit for H1 2025, even as revenue fell 5%, raising questions about underlying business dynamics.

HiTech Group Australia has reported its strongest financial year yet in FY25, with solid revenue growth and a robust balance sheet, while facing margin pressures in the first half of FY26 due to government spending shifts.

Coventry Group reports a challenging FY25 with revenue slipping 1.7% and EBITDA plunging 40.9%, but early FY26 results show promising recovery driven by cost cuts and ERP system stabilisation.

Oceania Healthcare reports a robust interim result for the six months to September 2025, with significant earnings growth, improved sales, and a reduction in debt gearing. The company’s strategic focus on cost control, capital management, and sustainable care delivery underpins its positive outlook despite housing market headwinds.

Monash IVF Group reported a 6.7% revenue increase to $271.9 million for FY25, alongside an 8.1% decline in underlying NPAT, aligning with prior guidance. The company outlined a cautious FY26 outlook focused on innovation, doctor retention, and cost management.

IPH Limited reported solid FY25 profit growth driven by Canadian acquisitions and a promising FY26 start despite challenges in Australia and New Zealand. CEO Andrew Blattman announced his retirement for late 2026, marking a pivotal leadership transition.